These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6311553)

  • 1. Effects of molsidomine and other NO-containing vasodilators on cyclic GMP formation.
    Böhme E; Grossman G; Spies C
    Eur Heart J; 1983 May; 4 Suppl C():19-24. PubMed ID: 6311553
    [No Abstract]   [Full Text] [Related]  

  • 2. Computer assisted drug analysis for dose-response curves, with special reference to molsidomine.
    Thulesius O; Stephen FX
    Gen Pharmacol; 1983; 14(1):91-3. PubMed ID: 6687463
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of platelet aggregation and stimulation of guanylate cyclase by an antianginal agent molsidomine and its metabolites.
    Nishikawa M; Kanamori M; Hidaka H
    J Pharmacol Exp Ther; 1982 Jan; 220(1):183-90. PubMed ID: 6118429
    [No Abstract]   [Full Text] [Related]  

  • 4. The effects of molsidomine and its metabolite SIN-1 on coronary vessel tone, platelet aggregation, and eicosanoid formation in vitro--inhibition of 12-HPETE biosynthesis.
    Darius H; Ahland B; Rücker W; Klaus W; Peskar BA; Schrör K
    J Cardiovasc Pharmacol; 1984; 6(1):115-21. PubMed ID: 6199592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of vasodilation by molsidomine.
    Kukovetz WR; Holzmann S
    Am Heart J; 1985 Mar; 109(3 Pt 2):637-40. PubMed ID: 2983523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of aspirin, molsidomine, trapidil, and some trapidil derivatives on arachidonic acid induced reversible thrombocyte aggregation in the rabbit.
    Zehl U; Mest HJ; Förster W
    Biomed Biochim Acta; 1984; 43(8-9):S381-4. PubMed ID: 6440554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of substituted sydnonimines on coronary smooth muscle relaxation and cyclic guanosine monophosphate levels.
    Rinaldi G; Cingolani H
    Circulation; 1983 Dec; 68(6):1315-20. PubMed ID: 6315260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic GMP as the mediator of molsidomine-induced vasodilatation.
    Kukovetz WR; Holzmann S
    Eur J Pharmacol; 1986 Mar; 122(1):103-9. PubMed ID: 3007172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation.
    Block HU; Förster W; Heinroth I
    Arzneimittelforschung; 1982; 32(3):189-94. PubMed ID: 6896278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasorelaxing actions of molsidomine and its metabolites, in comparison with nitroglycerin.
    Muramatsu I; Fujii K; Sakakibara Y; Fujiwara M
    Can J Physiol Pharmacol; 1983 Sep; 61(9):1071-8. PubMed ID: 6416660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of aspirin on the hemodynamic effects of molsidomine in healthy volunteers].
    Weber S; de Lauture D; Puechavy C; Pipeau C; Chazelle F; Degeorges M
    Therapie; 1986; 41(3):153-7. PubMed ID: 3529482
    [No Abstract]   [Full Text] [Related]  

  • 12. [Molsidomine, a coronary drug with platelet-aggregating inhibitory activity].
    Silberbauer K; Slany J; Sinzinger H; Punzengruber C
    Z Kardiol; 1982 Aug; 71(8):539-43. PubMed ID: 6753382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of molsidomine on coronary collateral blood flow in acute myocardial ischemia.
    Gross GJ; Gharaibeh M
    Eur J Pharmacol; 1980 Oct; 67(1):111-4. PubMed ID: 6893436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological basis of therapy with molsidomine].
    Bassenge E
    Herz; 1982 Oct; 7(5):296-306. PubMed ID: 6897544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of molsidomine and its active metabolite SIN-1 on fibrinolysis and platelet aggregation.
    Basista M; Grodzińska L; Swies J
    Thromb Haemost; 1985 Dec; 54(4):746-9. PubMed ID: 3911480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymic and nonenzymic release of NO accounts for the vasodilator activity of the metabolites of CAS 936, a novel long-acting sydnonimine derivative.
    Mülsch A; Hecker M; Mordvintcev PI; Vanin AF; Busse R
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Jan; 347(1):92-100. PubMed ID: 8383302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proceedings of the International Symposium on Molsidomine. November 5, 1983, Brussels, Belgium.
    Am Heart J; 1985 Mar; 109(3 Pt 2):625-724. PubMed ID: 3838397
    [No Abstract]   [Full Text] [Related]  

  • 18. Hemodynamic effects of molsidomine on weight sustaining isometric exercise in patients with ischemic heart disease.
    Tsujibayashi T; Niwa A; Taniguchi K; Takeuchi J
    Bull Tokyo Med Dent Univ; 1985 Dec; 32(4):163-7. PubMed ID: 3865742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of molsidomine on cardiac preload, coronary artery diameter, and coronary resistance.
    Bassenge E; Pohl U
    Am Heart J; 1985 Mar; 109(3 Pt 2):627-30. PubMed ID: 3838398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Redistribution of the coronary blood flow, functional improvement of the ischemic myocardium and reduction of the size of an experimental infarction by molsidomine].
    Berdeaux A; Giudicelli JF
    Ann Cardiol Angeiol (Paris); 1983 Dec; 32(8):511-5. PubMed ID: 6364947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.